부산대학교 도서관

This article explores the use of Dupilumab as a treatment for chronic urticaria (CU), a condition characterized by recurrent, itchy wheals and/or angioedema lasting more than 6 weeks. The study focuses on seven patients with severe atopic dermatitis and CU who were treated with Dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4 and IL-13 signaling. The results showed positive outcomes, including improvements in urticarial control, eczema severity, quality of life, and sleep scores. However, larger controlled studies are needed to fully understand the effectiveness of Dupilumab and determine the best treatment approach for different types of CU. [Extracted from the article]